Dr. Prash Puspanathan, a consultant psychiatrist and co-founder of Enosis Therapeutics, discusses the high costs of psychedelic-assisted therapy, primarily due to the intensive human resource requirements. He highlights ongoing efforts to reduce costs through innovative delivery models, while emphasizing the critical role of insurance companies and potential policy changes in making these therapies more accessible and mainstream.